Evidence map›Paper›PMID 27939096›Full record

ArticleClinics and research in hepatology and gastroenterology2017

Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.

Emilie Decaup, Julia Rochotte, Stéphane Pyronnet, Corinne Bousquet, Christine Jean

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinics and research in hepatology and gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Emilie DecaupUMR 1037 INSERM-UPS ERL CNRS 5294, Cancer Research Center of Toulouse, Tumor Biology Department, Team 6, 31037 Toulouse, France.
Julia RochotteUMR 1037 INSERM-UPS ERL CNRS 5294, Cancer Research Center of Toulouse, Tumor Biology Department, Team 6, 31037 Toulouse, France.
Stéphane PyronnetUMR 1037 INSERM-UPS ERL CNRS 5294, Cancer Research Center of Toulouse, Tumor Biology Department, Team 6, 31037 Toulouse, France.
Corinne BousquetUMR 1037 INSERM-UPS ERL CNRS 5294, Cancer Research Center of Toulouse, Tumor Biology Department, Team 6, 31037 Toulouse, France.
Christine JeanUMR 1037 INSERM-UPS ERL CNRS 5294, Cancer Research Center of Toulouse, Tumor Biology Department, Team 6, 31037 Toulouse, France. Electronic address: christine.jean@inserm.fr.
Inserm · FRCentre de Recherche en Cancérologie de Toulouse · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a deadly cancer, characterized by a uniquely immunosuppressive and fibrotic microenvironment responsible for its high chemoresistance. Jiang et al. identify FAK (focal adhesion kinase) activity as an interesting therapeutic target, the inhibition of which drastically reduces PDAC microenvironment deleterious features. In combination with gemcitabine and immune-checkpoint therapy, FAK inhibitor promotes long-term tumor stasis with extended survival in PDAC mouse models. In conclusion, Jiang et al. provide proof of concept that FAK inhibitors combined with chemotherapy will highly profit PDAC patients.

Indexed as

AdenocarcinomaCarcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsFocal Adhesion Protein-Tyrosine KinasesHumansMiceTumor MicroenvironmentFocal Adhesion Protein-Tyrosine Kinases

Identifiers

PMID27939096
OpenAlexW2559878140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.